Healthcare / BiotechnologyNasdaqGS
$7.12
-0.05 (-0.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $38.9M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$362M
P/E
14.8x
↓EV/EBITDA
6.7x
↓ROE
23.9%
↑Gross Margin
74.5%
↑Debt/Equity
0.22
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
18.3%
FCF / Net income
1.34x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $228.4M · net income $31.1M · FCF $41.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $228.4M | $228.4M | $230.5M | $235.6M | $228.0M | $253.2M | $225.1M | $272.3M | $251.0M | $27.7M | — | — | — | — | — | — |
| Net Income | $31.1M | $31.1M | $30.3M | $21.6M | $2000.00 | $-29.1M | $-60.0M | $-75.6M | $-113.6M | $-292.0M | $-276.0M | $-239.3M | $-142.0M | $-54.7M | $-74.4M | $-10.2M |
| EBITDA | $53.3M | $53.3M | $48.1M | $47.5M | $21.9M | $12.6M | $-20.4M | $-31.0M | $-87.3M | $-289.6M | $-275.4M | $-239.5M | $-141.6M | $-54.4M | $-74.2M | $-10.1M |
| EPS | 0.61 | 0.61 | 0.62 | 0.45 | — | -0.72 | -1.52 | -75595.00 | — | — | — | — | — | — | — | — |
| Gross Margin | 74.5% | 74.5% | 72.1% | 73.4% | 75.8% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 16.3% | 16.3% | 13.4% | 13.9% | 13.5% | 0.5% | -13.5% | -14.3% | -37.7% | -1056.1% | — | — | — | — | — | — |
| Net Margin | 13.6% | 13.6% | 13.1% | 9.2% | 0.0% | -11.5% | -26.7% | -27.8% | -45.3% | -1054.6% | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.22 | 0.22 | 0.80 | 2.09 | 5.29 | -39.69 | -14.12 | 5.44 | 4.43 | 0.91 | — | — | — | — | — | — |
| Current Ratio | 2.38 | 2.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $41.7M | $41.7M | $38.9M | $14.4M | $-22.8M | $20.6M | $727000.00 | $22.1M | $-24.5M | $-172.9M | $-146.0M | — | — | $-101.5M | — | $-2.1M |
| Returns | ||||||||||||||||
| ROE | 23.9% | 23.9% | 32.9% | 40.4% | 0.0% | 1190.8% | 1008.1% | -432.9% | -331.1% | -547.7% | -131.5% | -116.2% | -121.3% | -65.1% | -57.7% | -18.8% |
| Valuation | ||||||||||||||||
| P/E | 14.83 | 14.83 | 4.76 | 10.42 | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 6.74 | 6.74 | 3.11 | 5.26 | 11.63 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 2.77 | 2.77 | 1.57 | 4.17 | 10.02 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | -0.9% | -0.9% | -2.2% | 3.3% | — | 12.5% | -17.3% | 8.5% | 806.6% | — | — | — | — | — | — | — |
| EPS Growth | -1.6% | -1.6% | 37.8% | — | — | 52.6% | 100.0% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.2%
EPS terminal req.
$0.63
Spread vs growth
-2.8%
5Y implied EPS CAGR
4.6%
EPS terminal req.
$0.76
Spread vs growth
-6.2%
10Y implied EPS CAGR
7.3%
EPS terminal req.
$1.23
Spread vs growth
-8.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+117.1%
Start / end P/E
5.3x → 11.7x
EPS bridge
0.62 → 0.61
Residual
-1.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.